Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;51(2):293-300.
doi: 10.1007/s10396-023-01398-5. Epub 2023 Dec 26.

VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response

Tomomitsu Matono  1   2   3 , Toshifumi Tada  4   5 , Takashi Nishimura  4   6 , Tomoyuki Takashima  4 , Nobuhiro Aizawa  4 , Naoto Ikeda  4 , Hideyuki Shiomi  4 , Hirayuki Enomoto  4 , Hiroko Iijima  4   6
Affiliations

VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response

Tomomitsu Matono et al. J Med Ultrason (2001). 2024 Apr.

Erratum in

Abstract

Purpose: Risk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. This study investigated the usefulness of the VFMAP scoring system for predicting the development of HCC in these patients.

Methods: This study included 358 patients with HCV who achieved SVR after DAA treatment. The VFMAP system defines and scores cutoff values for virtual touch quantification (VTQ), fasting plasma glucose, sex, age, and alpha-fetoprotein values. All patients were grouped according to their VFMAP scores as follows: 0 or 1 point, low-score group; 2 or 3 points, intermediate-score group; and 4 or 5 points, high-score group.

Results: Nineteen patients developed HCC. The median follow-up duration was 3.2 (1.5-4.0) years. The respective cumulative incidence rates of HCC at 12, 24, and 36 months were as follows in different subgroups: all study patients, 3.0%, 4.8%, and 6.6%; low-score group, 0.96%, 0.96%, and 0.96%; intermediate-score group, 2.6%, 4.5%, and 6.8%; and high-score group, 10.0%, 15.3%, and 18.5%. The cumulative incidence rates of HCC in the high-score group were significantly higher than those in the low- and intermediate-score groups (p < 0.001 and < 0.05, respectively).

Conclusion: VFMAP accurately predicted the development of HCC in HCV patients who achieved SVR following treatment with DAAs.

Keywords: Direct-acting antiviral; Hepatocellular carcinoma; Sustained virological response; VFMAP scoring system.

PubMed Disclaimer

Conflict of interest statement

Toshifumi Tada: Lecture fees from AbbVie, Chugai Pharmaceutical, and Eisai. Takashi Nishimura and Hiroko Iijima: Lecture fees from Otsuka Pharmaceutical and research funding from Canon Medical Systems and GE Healthcare Japan. None of the other authors have potential conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Cumulative incidence rates of hepatocellular carcinoma. The 12-, 24-, and 36-month cumulative incidence rates of HCC were 3.0%, 4.8%, and 6.6%, respectively
Fig. 2
Fig. 2
The respective Kaplan–Meier curves for the 12-, 24-, and 36-month cumulative incidence rates of hepatocellular carcinoma according to subgroup: in the low-score group, 0.96%, 0.96%, and 0.96%; in the intermediate-score group, 2.6%, 4.5%, and 6.8%; and in the high-score group, 10.0%, 15.3%, and 18.5%
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76. - PubMed
    1. Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–76. - PMC - PubMed
    1. European Association for the Study of the Liver, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative: Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218. - PubMed
    1. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with directacting antiviral agents. Gastroenterology. 2017;153:996–1005. - PubMed
    1. Nahon P, Layese R, Bourcier V, et al. ANRS CO12 CirVir Group Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436–50. - PubMed

LinkOut - more resources